Hudson Canyon Capital Management’s AbbVie ABBV Stock Holding History

Hudson Canyon Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.76M	Buy	10,959 +1,603	+17%	+$345K	1.48%	27
2026 Q1	$2.03M	Sell	9,356 -51	-0.5%	-$11.3K	1.25%	40
2025 Q4	$2.15M	Hold	9,407	–	–	1.26%	37
2025 Q3	$1.99M	Sell	9,407 -323	-3%	-$65.8K	1.15%	41
2025 Q2	$1.81M	Buy	9,730 +180	+2%	+$33.5K	1.12%	48
2025 Q1	$2M	Sell	9,550 -250	-3%	-$48.6K	1.41%	34
2024 Q4	$1.74M	Buy	9,800 +1,150	+13%	+$211K	1.14%	42
2024 Q3	$1.71M	Buy	+8,650	New	+$1.61M	1.1%	48
2023 Q2	–	Sell	-11,089	Closed	-$1.77M	–	56
2023 Q1	$1.77M	Sell	11,089 -668	-6%	-$102K	1.48%	35
2022 Q4	$1.9M	Sell	11,757 -258	-2%	-$39.6K	1.75%	21
2022 Q3	$1.61M	Hold	12,015	–	–	1.6%	25
2022 Q2	$1.84M	Buy	12,015 +1,715	+17%	+$262K	1.77%	18
2022 Q1	$1.67M	Buy	+10,300	New	+$1.5M	1.32%	44

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Hudson Canyon Capital Management's ABBV Position: Q2 2026 in Review

Hudson Canyon Capital Management increased its AbbVie (ABBV) stake by 17% in Q2 2026, buying an estimated $345K and bringing the position to 10,959 shares worth $2.76M. The position accounts for 1.48% of the portfolio, ranked #27.

Hudson Canyon Capital Management first reported a position in ABBV in Q1 2022 and has held it in 13 quarters since. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Hudson Canyon Capital Management held 10,959 shares of AbbVie worth $2.76M as of Q2 2026.
Hudson Canyon Capital Management bought 1,603 AbbVie shares in Q2 2026, an estimated $345K.
AbbVie made up 1.48% of Hudson Canyon Capital Management's portfolio in Q2 2026, its #27 holding.
Hudson Canyon Capital Management first reported a position in AbbVie in Q1 2022 and has held it in 13 quarters since.
4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hudson Canyon Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.